Men’s health blood tests can help evaluate testosterone status, pituitary-to-testis signaling, selected causes of sexual symptoms, prostate-related risk, treatment safety, and cardiometabolic health. The most useful starting test for suspected testosterone deficiency is usually a properly timed morning total testosterone measurement, repeated on a separate morning if low; free testosterone, SHBG, albumin, LH, FSH, prolactin, or estradiol may add context when clinically indicated. PSA testing may support prostate-cancer risk assessment or follow-up, but PSA is not a cancer diagnosis. Symptoms, timing, illness, body weight, sleep, medications, prior results, and examination findings all matter, and urgent symptoms require prompt professional care.
For a broader view of specimens, panels, screening, monitoring, and test selection, begin with The Complete Guide to Lab Tests and Blood Work. Use this page alongside How to Read and Understand Your Lab Results and Direct-Access Lab Testing: How It Works and What to Expect.
| Core test or test group | Common specimen | Fasting or timing need | Primary purpose | Common use status | Major limitation |
|---|---|---|---|---|---|
| Total testosterone | Blood | Prefer early morning; fasting is commonly recommended for confirmation | Initial assessment when symptoms or signs raise concern; treatment monitoring in a clinician-directed plan | Common or first-line | One low result does not diagnose testosterone deficiency; assay and biological variation matter |
| Free testosterone with SHBG and, when calculated, albumin | Blood | Usually collected with morning total testosterone | Clarifies available testosterone when total testosterone is borderline or SHBG may be altered | Risk-based or targeted | Methods and reference intervals differ; direct analog free-testosterone methods may be less reliable |
| LH and FSH | Blood | No universal fasting need; interpret after confirmed biochemical concern | Helps distinguish a testicular pattern from a pituitary/hypothalamic pattern | Risk-based or targeted | Cannot identify a cause by themselves; specialist evaluation or imaging may still be needed |
| Prolactin and estradiol | Blood | Prolactin may be affected by stress, exercise, sex, sleep, and medications; use consistent conditions | Selected evaluation of pituitary clues, breast symptoms, or treatment-related questions | Risk-based or targeted | Not appropriate as automatic broad screening tests in every man |
| Total PSA | Blood | Avoid transient influences according to collection instructions; disclose urinary symptoms, procedures, and relevant drugs | Shared-decision screening, symptom evaluation, or prostate-condition monitoring | Risk-based or targeted | PSA can rise from benign conditions and can be low despite cancer; it is not diagnostic |
| Free PSA and percent free PSA | Blood | Collect with total PSA under the same preparation conditions | Adds context to selected total-PSA results and risk discussions | Risk-based or targeted | No universal percentage independently proves or excludes cancer |
| CBC with hematocrit | Blood | No routine fasting need | Baseline and safety monitoring during clinician-managed testosterone therapy; evaluates anemia or erythrocytosis | Monitoring | Abnormal hematocrit has many causes and should not be interpreted as a dose instruction |
| CMP, lipid panel, and A1C | Blood | Fasting depends on the chosen tests and clinical question | Assesses liver, kidney, glucose, and cardiovascular context that may overlap with symptoms or treatment risk | Common or first-line / monitoring | These tests do not diagnose testosterone deficiency or explain sexual symptoms by themselves |
| TSH with free T4 and selected nutrient or anemia tests | Blood | Preparation varies | Evaluates alternative contributors to fatigue, weight change, libido concerns, or erectile symptoms | Risk-based or targeted | Should be selected from the history rather than ordered as an unfocused “everything” panel |
A larger panel is not automatically more informative. The best test set is the smallest group that can answer a defined question while minimizing false-positive findings, incidental abnormalities, cost, and unnecessary follow-up.
Men’s health blood tests are laboratory measurements used to investigate or monitor questions involving androgen production, pituitary signaling, sexual and reproductive function, prostate-related risk, treatment safety, and cardiometabolic health. They do not form one universal “men’s panel.” The appropriate tests depend on the question being asked.
The testosterone system involves the hypothalamus, pituitary gland, testes, liver-produced binding proteins, and target tissues. The pituitary hormones LH and FSH help regulate testosterone production and sperm development. SHBG and albumin bind circulating testosterone and influence how total and free testosterone relate to one another. Prolactin, thyroid function, liver health, body composition, sleep, illness, and medications can alter symptoms or results.
Prostate testing is a separate but often overlapping domain. PSA is made by prostate cells and may rise with cancer, benign enlargement, inflammation, infection, urinary retention, procedures, or other influences. A PSA result can support a risk conversation or follow-up plan, but it cannot determine by itself whether cancer is present. [9]
Symptoms alone are often insufficient. Fatigue, low libido, reduced erections, mood changes, weight gain, poor exercise recovery, and sleep problems have many possible causes. Objective laboratory testing may add evidence, but the results still need a medical history, examination, medication review, and sometimes imaging, semen analysis, sleep testing, cardiovascular assessment, or specialist evaluation.
Focused testing can help distinguish a persistent biochemical pattern from a temporary or misleading result. Testosterone varies during the day and may fall during acute illness, sleep disruption, calorie restriction, or other physiological stress. Obesity can lower SHBG and therefore lower total testosterone without producing the same free-testosterone pattern in every person. Liver and thyroid disorders, certain medications, and assay differences can also alter interpretation.
Hormone and sexual symptoms may overlap with cardiometabolic risk. Erectile dysfunction can precede or accompany vascular disease, diabetes, hypertension, dyslipidemia, smoking-related disease, or medication effects. The American Urological Association identifies ED as a possible marker of underlying cardiovascular disease, which is why an ED evaluation should not be reduced to testosterone alone. [6]
Testing may also establish a baseline before clinician-managed hormone treatment or help monitor a known condition. Monitoring is not limited to a testosterone number: formulation-specific timing, symptoms, adverse effects, CBC/hematocrit, prostate-risk discussions, and selected metabolic markers may matter. Laboratory monitoring supports—but does not replace—the prescribing clinician’s assessment.
PSA screening has potential benefits and harms. Guidelines emphasize informed or shared decision-making rather than automatic screening for every man. False-positive results, overdiagnosis, biopsy complications, and treatment-related urinary or sexual effects must be weighed against the possibility of detecting clinically important disease earlier. [7] [8] [9]
| Question | What testing may add | Important boundary |
|---|---|---|
| Androgen status | Whether measured total testosterone is low, in-range, or high relative to the reporting laboratory; free testosterone may add context when indicated | Requires symptoms, repeat morning testing, and method-aware interpretation |
| Binding-protein effects | Whether SHBG and albumin may help explain a mismatch between total and free testosterone | Does not prove why SHBG is abnormal |
| Pituitary–testicular signaling | LH and FSH patterns may help localize whether a confirmed androgen problem appears more testicular or more pituitary/hypothalamic | Does not replace evaluation for the underlying cause |
| Selected pituitary or estrogen-related clues | Prolactin and estradiol can add information in defined clinical situations | Broad screening can generate incidental findings and false alarms |
| Prostate-related risk context | PSA level, trend, and selected free-PSA measures can inform a risk discussion | Only tissue evaluation can establish prostate cancer |
| Blood-cell response | CBC and hematocrit can identify anemia, elevated red-cell concentration, or other blood-count abnormalities | Does not identify every cause and does not dictate treatment changes alone |
| Cardiometabolic context | Lipids, A1C, glucose, insulin in selected cases, liver and kidney markers can identify relevant risk patterns | Does not prove that a metabolic abnormality caused a sexual or hormone symptom |
| Trend over time | Repeated measurements under similar conditions may show whether a finding persists or changes | A trend can still be influenced by methods, timing, health status, and treatment |
| Laboratory testing cannot determine | Other evaluation that may be needed |
|---|---|
| A definitive diagnosis from one value | Clinical history, physical examination, repeat or confirmatory testing |
| Whether a symptom is caused by testosterone | Assessment for sleep disorders, depression, medication effects, thyroid disease, anemia, diabetes, vascular disease, relationship factors, and other causes |
| Fertility potential from hormone blood tests alone | Semen analysis, reproductive history, examination, and sometimes specialist testing |
| Whether an elevated PSA is cancer | Repeat PSA when appropriate, clinical examination, urine testing, risk tools, prostate imaging, and/or biopsy |
| Prostate size, urinary obstruction, or urinary retention severity | Physical examination, post-void residual measurement, urine studies, imaging, or urologic evaluation |
| The cause of sudden testicular pain | Immediate examination and often urgent imaging; routine outpatient testing must not delay care |
| Cardiovascular fitness or coronary anatomy | Blood pressure measurement, electrocardiography, exercise testing, imaging, or specialist evaluation when indicated |
| Whether a medication or hormone dose should change | Prescriber review integrating symptoms, timing relative to formulation, safety results, and treatment goals |
Nonlaboratory evaluation may include a genital, prostate, vascular, neurologic, or breast examination; blood-pressure measurement; electrocardiography or cardiac testing; sleep studies; pituitary or prostate imaging; prostate biopsy; bone-density testing; semen analysis; genetic counseling; or mental-health and relationship assessment. The need depends on symptoms, risk, and prior findings.
No symptom in this table confirms a hormone, prostate, sexual, or metabolic disorder. It is a map of questions that may guide focused evaluation.
| Scenario | Possible explanations | Laboratory tests that may add information | Nonlaboratory evaluation that may be needed | Safety or urgency note |
|---|---|---|---|---|
| Low libido, reduced morning erections, fatigue, or loss of strength | Testosterone deficiency is one possibility; sleep loss, obesity, depression, thyroid disease, anemia, medications, acute illness, and relationship factors are also common | Morning total testosterone; repeat if low; selected free testosterone/SHBG, CBC, TSH/free T4, A1C, or other focused tests | History, examination, sleep and medication review | Routine evaluation is appropriate unless symptoms are sudden or accompanied by emergency warning signs |
| Erectile dysfunction | Vascular, metabolic, neurologic, medication-related, hormonal, structural, sleep-related, or psychological contributors | A1C, lipids, glucose/CMP, and morning testosterone; prolactin or thyroid tests only when indicated | Blood pressure, cardiovascular risk assessment, genital/vascular/neurologic examination, medication and psychosocial review | Chest pain, severe shortness of breath, fainting, or new neurologic symptoms require emergency evaluation |
| Infertility or pregnancy delay | Sperm-production problems, obstruction, genetic factors, testicular injury, medication or hormone exposure, endocrine causes | FSH and LH, morning testosterone, prolactin in selected cases | Semen analysis is central; reproductive-urology evaluation may be needed | Exogenous testosterone can suppress sperm production; treatment decisions belong with a clinician |
| Breast tenderness or enlargement | Medication effects, body-fat-related aromatization, liver disease, thyroid disease, testicular or other causes | Estradiol, testosterone, liver tests, and selected additional tests based on examination | Breast and testicular examination; imaging when indicated | A new hard breast or testicular mass needs prompt clinical assessment |
| Headaches, visual changes, low testosterone pattern, or unexplained nipple discharge | Pituitary or medication-related causes are among the possibilities | Prolactin, repeat under controlled conditions if mildly elevated; LH/FSH and other pituitary tests as directed | Neurologic and visual-field evaluation; pituitary imaging may be required | Sudden severe headache, new vision loss, weakness, or confusion requires urgent or emergency care |
| Weak stream, urgency, frequent urination, nighttime urination, or pelvic discomfort | Benign prostate enlargement, infection/inflammation, bladder problems, medication effects, and prostate cancer are among many possibilities | PSA when appropriate; urinalysis or other tests based on symptoms | Examination, urine testing, post-void residual, imaging, or urology review | Inability to urinate, fever with systemic illness, or heavy bleeding requires prompt care |
| Considering or already receiving clinician-managed testosterone therapy | Need to confirm the indication, establish safety context, and monitor response/adverse effects | Testosterone timed to formulation, CBC/hematocrit, PSA when appropriate, and selected metabolic tests | Prescriber assessment, blood pressure, sleep-apnea and fertility review, prostate discussion | Do not start, stop, or change therapy from laboratory values alone |
| Obesity, disrupted sleep, acute illness, major calorie restriction, opioid or corticosteroid use | Potentially reversible or confounding influences on testosterone and symptoms | Delay elective confirmation until clinically stable when appropriate; use repeat morning testing and focused metabolic evaluation | Medication review, sleep evaluation, nutrition and illness assessment | Never stop a prescribed medicine solely to improve a laboratory result |
| Sudden severe testicular pain or swelling | Testicular torsion, infection, trauma, or other urgent conditions | Routine hormone panels are not the first step | Immediate examination and often urgent ultrasound | Emergency evaluation is time-sensitive |
These are frequently used when a defined clinical question supports testing. For possible testosterone deficiency, the usual laboratory starting point is a properly timed early-morning total testosterone measurement—not an indiscriminate multi-hormone panel. For shared-decision prostate screening or prostate-related follow-up, total PSA is generally the starting blood marker. CBC, CMP, A1C, and a lipid panel may be first-line when symptoms or ED suggest anemia, glucose, liver, kidney, or cardiovascular contributors.
Free testosterone, SHBG, albumin, LH, FSH, prolactin, estradiol, DHEA-S, thyroid tests, iron studies, and free PSA are most useful when a specific history, symptom, medication, previous result, or discordant pattern creates a reason to order them. Targeted testing limits incidental findings and improves interpretability.
Monitoring tests track a known condition, a documented trend, or clinician-managed treatment. During prescribed testosterone therapy, the plan may include formulation-aware testosterone timing, CBC/hematocrit, symptoms and adverse effects, risk-appropriate PSA follow-up, and selected metabolic or liver tests. After prostate-cancer treatment, PSA monitoring follows a specialist-defined protocol that differs from screening.
Specialist-directed testing includes pituitary evaluation after a supported central hormone pattern, genetic or chromosomal testing, testicular tumor markers, specialized prostate biomarkers, post-prostatectomy PSA interpretation, and fertility investigations that integrate semen analysis. These tests can be valuable but are easily misapplied without the correct pretest context.
New prostate biomarkers, urine tests, imaging-integrated risk models, and some hormone-metabolite or “biological age” panels continue to evolve. An emerging test may improve risk stratification in selected settings, but availability does not prove that broad screening improves outcomes. The National Cancer Institute notes that several blood, urine, and imaging approaches are under study; they do not replace established diagnostic pathways. [9]
Routine screening of asymptomatic men with testosterone or a large hormone panel is not recommended by the Endocrine Society. [1] [2] Prolactin, estradiol, DHEA-S, LH, FSH, and free testosterone should not be bundled automatically without a clinical reason. PSA should not be framed as a universal annual cancer test; screening decisions should account for age, risk, previous results, health status, preferences, and the recommendations being followed.
| Measure | What it represents | When it may be useful | Strength | Main limitation | Interpretation safeguard |
|---|---|---|---|---|---|
| Total testosterone | All measured testosterone in serum: protein-bound plus unbound fractions | Usual initial laboratory measurement when symptoms or signs raise concern | Widely available; most guideline pathways begin here | Can look low or high when SHBG is altered; varies with time of day, illness, energy balance, sleep, and assay | Collect on a separate early morning for confirmation if the first result is low; interpret with symptoms and the laboratory method |
| Free testosterone | The small fraction not bound to SHBG or albumin; may be measured by equilibrium dialysis or estimated with validated calculations | Useful when total testosterone is near a decision threshold, symptoms and total testosterone are discordant, or altered SHBG is suspected | Can clarify biologically available androgen exposure when binding proteins distort total testosterone | Method-dependent; direct analog assays and different calculations are not interchangeable; reference intervals vary | Prefer a reliable method and interpret with simultaneous total testosterone, SHBG, and—when calculation is used—albumin |
| Sex hormone–binding globulin (SHBG) | The principal high-affinity binding protein for testosterone and estradiol | Explains why total and free testosterone may not move together | Adds context in obesity, insulin resistance, thyroid or liver disease, aging, and selected medication/hormone exposures | SHBG itself is not a measure of androgen action and does not diagnose a disease | Use with total testosterone; review health conditions and medicines that can alter SHBG |
| Albumin | A lower-affinity testosterone-binding protein and a general liver/nutrition marker | Included in some validated calculated free- or bioavailable-testosterone equations | Improves calculation context and may reveal broader health issues | Small changes may have limited impact; a calculated result depends on the equation and input assays | Use the same-day value when the chosen calculation requires it |
| Bioavailable testosterone | Free testosterone plus testosterone loosely bound to albumin | Selected situations where a laboratory reports a validated measured or calculated value | Offers another view of tissue-accessible testosterone | Less standardized across laboratories and not required for every evaluation | Confirm what method and reference interval the reporting laboratory uses |
Most circulating testosterone is protein-bound. Total testosterone is therefore affected not only by testosterone production but also by binding-protein concentrations. Free testosterone can add context when total testosterone is near a decision point or when SHBG is likely to be altered. Albumin may be required for a calculated estimate. The reliability of the assay or calculation matters; results produced by different methods are not automatically interchangeable.
The interpretation language below is intentionally general. “High,” “low,” “positive,” or “negative” does not equal a diagnosis, and a result should be interpreted with the laboratory method, reference interval, collection conditions, symptoms, and related results.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Testosterone Total Test TT, total T, total testosterone Use status: First-line | Measures bound plus unbound testosterone for an initial biochemical assessment when compatible symptoms or signs are present and for clinician-directed monitoring. A result below the reporting laboratory’s interval may support concern only when persistent and clinically concordant; a high result may reflect hormone exposure, supplements, assay effects, or an endocrine disorder.1 | Serum. Although the product lists no special preparation, diagnostic evaluation generally uses an early-morning sample after usual sleep; confirm a low result on a separate morning, commonly while fasting. Time of day, illness, calorie restriction, sleep, obesity, opioids, glucocorticoids, anabolic agents, and assay method may alter results. It cannot diagnose testosterone deficiency, identify its cause, or justify treatment by itself. |
| Testosterone Free and Total Test FT, free T, calculated free testosterone, equilibrium-dialysis free testosterone Use status: Targeted | Measures unbound testosterone together with the total concentration. It may add context when the total result is borderline, symptoms and results are discordant, or altered binding proteins are suspected. High or low values remain method- and laboratory-interval dependent.12 | Serum; the product lists no special preparation. When a calculated method is used, collect the related binding-protein and albumin measurements at the same time. Binding-protein concentration, albumin, the calculation equation, assay method, acute illness, and hormone exposure may alter results. It cannot replace confirmation of a low total result or establish androgen activity in tissues. |
| Sex Hormone Binding Globulin Test SHBG, TeBG, testosterone-estrogen binding globulin Use status: Targeted | Measures the protein that binds testosterone and estradiol and helps explain differences between total and unbound hormone. Lower SHBG often corresponds to a larger unbound fraction, while higher SHBG often corresponds to a smaller one; the cause requires clinical context.2 | Serum. There is no universal fasting requirement; collect it with the androgen measurements being interpreted and follow product instructions. Obesity, insulin resistance, thyroid or liver disease, aging, estrogen or androgen exposure, selected medicines, and assay interference may affect results. It cannot diagnose testosterone deficiency or identify the cause of an abnormal hormone result alone. |
| Albumin Test ALB, serum albumin Use status: Targeted | Measures the main circulating protein and a lower-affinity testosterone-binding protein. It supports selected calculated free- or bioavailable-testosterone methods and adds liver, kidney, inflammatory, and nutritional context. An abnormal value can change a hormone calculation and may point to a nonhormonal health issue.1 | Serum; no special preparation is listed for the product. Hydration, liver disease, kidney protein loss, inflammation, and nutritional status may alter results. It cannot diagnose androgen deficiency or malnutrition by itself. |
| LH Test LH, luteinizing hormone, lutropin, interstitial cell-stimulating hormone, ICSH Use status: Targeted | Measures the pituitary signal that stimulates testicular testosterone production. After biochemical concern is confirmed, higher LH with a low androgen result may fit a testicular pattern; low or inappropriately normal LH may fit a pituitary or hypothalamic pattern.13 | Serum; no special preparation is listed. Pulsatile secretion, acute illness, medicines, pituitary or testicular conditions, and hormone therapy may alter results. Interpret it with the androgen result and clinical context; one value cannot identify a specific pituitary or testicular disorder. |
| FSH Test FSH, follicle-stimulating hormone, follitropin Use status: Targeted | Measures a pituitary signal involved in sperm production and testicular function. Higher values may suggest impaired spermatogenic or testicular function; low or inappropriately normal values may occur in central pituitary or hypothalamic patterns.13 | Serum; no special preparation is listed. Hormone therapy, illness, and pituitary or testicular conditions may affect results. Interpret it with reproductive history and related hormone findings. It cannot determine sperm count, motility, or fertility by itself. |
| Prolactin Test PRL, prolactin Use status: Targeted | Measures a pituitary hormone. It may be ordered for a low-testosterone pattern with central features, sexual or breast symptoms, nipple discharge, headaches, visual symptoms, or possible medication effects. A persistent elevation can suppress reproductive signaling; a mild isolated elevation is often nonspecific and may need confirmation.3 | Serum; the linked product prefers fasting but does not require it. Use a calm, standardized collection and follow timing instructions. Sleep, stress, exercise, sexual activity, chest-wall stimulation, kidney disease, hypothyroidism, and many medicines may affect results. One elevated value cannot diagnose a pituitary tumor. |
| Estradiol Ultrasensitive Test E2, sensitive estradiol, ultrasensitive estradiol Use status: Targeted | Measures estradiol at concentrations relevant to selected male evaluations. It may be used for breast symptoms, suspected estrogen excess or deficiency, or clinician-directed therapy monitoring. High or low values require context from symptoms, androgen status, body composition, liver function, medicines, and assay method.3 | Serum; no special preparation is listed. Use a method suitable for lower concentrations when clinically indicated and follow therapy-specific timing instructions. Obesity, liver disease, alcohol, aromatase activity, medicines, testosterone exposure, and assay sensitivity may affect results. It cannot explain every sexual, mood, or breast symptom and is not a universal screening test during testosterone therapy. |
| DHEA-S Test DHEA-S, DHEAS, dehydroepiandrosterone sulfate Use status: Specialist-directed | Measures a relatively stable adrenal androgen. It may support selected evaluation of suspected adrenal androgen excess or deficiency but is not a routine low-testosterone test. An abnormal result may prompt review of adrenal, age-related, medication, supplement, and other factors.3 | Serum. Follow product instructions and disclose DHEA, biotin, other supplements, and medicines. Age, adrenal disease, supplements, medicines, and assay interference may alter results. It cannot diagnose “adrenal fatigue,” testosterone deficiency, or a need for supplementation. |
| TSH and Free T4 Test thyrotropin and FT4, TSH with free thyroxine Use status: Targeted | Measures the pituitary thyroid signal and unbound thyroxine to evaluate thyroid contributors to fatigue, weight change, sexual symptoms, or altered hormone binding. High TSH with low free T4 or low TSH with high free T4 may support a thyroid-dysfunction pattern; discordant results require clinical interpretation.3 | Serum; no special preparation is listed. Acute illness, biotin and other supplements, thyroid medicines, pituitary disease, and assay interference may affect results. Follow laboratory and prescriber instructions. The pair cannot establish that thyroid status caused a sexual or testosterone-related symptom. |
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| PSA Total Test PSA, total PSA, prostate-specific antigen Use status: Targeted | Measures total circulating prostate-specific antigen. It may be used after shared decision-making about screening, to evaluate prostate-related symptoms, or to monitor a known prostate condition or treatment. A higher result may reflect cancer, benign enlargement, inflammation, infection, or a temporary influence; a lower result does not exclude cancer.4 | Serum; no fasting is required. Follow product instructions and disclose urinary symptoms, recent procedures, and medicines. Age, prostate size, infection or inflammation, ejaculation, cycling, biopsy or instrumentation, and medicines such as finasteride or dutasteride may affect results. It cannot diagnose, stage, or exclude prostate cancer. |
| Free PSA in the PSA Free and Total Test fPSA, unbound PSA, free prostate-specific antigen Use status: Targeted | Measures the unbound fraction and adds context to selected nondefinitive total results when further evaluation is being considered. A lower free fraction may be associated with greater cancer probability in some populations, but results overlap substantially between benign and malignant conditions.4 | Serum; collect it with the total measurement under the same conditions. The same temporary influences that affect total PSA and differences between assay methods may alter interpretation. It cannot diagnose cancer or establish a universal biopsy threshold. |
| Percent Free PSA in the PSA Free and Total Test % free PSA, free-to-total PSA ratio, percent fPSA Use status: Targeted | Calculates the free-to-total ratio for risk stratification in selected men with a nondefinitive total result. Lower percentages are associated with a greater likelihood of cancer on biopsy in studied populations, but no single percentage is diagnostic or universally applicable.4 | Calculated from simultaneously collected serum free and total measurements. Assay method, the total-result range, prostate conditions, and the population being evaluated affect interpretation. It cannot prove or rule out malignancy and should not be read without age, risk factors, examination findings, and trends. |
| Post-Prostatectomy PSA Test ultrasensitive PSA, uPSA, post-prostatectomy PSA Use status: Specialist-directed | Measures very low PSA concentrations after surgical removal of the prostate for specialist-directed treatment follow-up. A detectable or rising result requires method-aware interpretation by the treating team and may warrant confirmation or other evaluation.5 | Serum; no special preparation is listed. When possible, use the same laboratory method and follow the treating team’s schedule. Assay sensitivity, a laboratory-method change, residual benign tissue, and timing after treatment may affect results. It is not for routine screening in a person with a prostate and cannot establish recurrence by itself. |
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Complete Blood Count with Differential and Platelets – CBC Test CBC, CBC with differential, Hgb, Hct, full blood count Use status: Monitoring | Measures red cells, hemoglobin, hematocrit, white cells, and platelets. It evaluates anemia and provides baseline or follow-up information during clinician-managed testosterone therapy. Low red-cell measures may fit anemia; high hemoglobin or hematocrit may reflect erythrocytosis, dehydration, altitude, smoking, sleep apnea, lung disease, or therapy.16 | Whole blood; no routine fasting is needed. Hydration, altitude, smoking, sleep apnea, recent exercise, and illness may affect results; comparable collection conditions help with trends. It cannot determine the cause of an abnormal count or direct a hormone-dose change by itself. |
| Comprehensive Metabolic Panel Test – CMP CMP, chemistry panel, metabolic panel Use status: Monitoring | Measures glucose, electrolytes, kidney markers, liver-associated enzymes, and proteins for broad safety and alternative-cause context. Abnormal values may suggest a glucose, hydration, electrolyte, liver, or kidney concern that requires follow-up; they do not establish one specific disorder.6 | Serum; fasting is preferred by the linked product but is not required. Fasting status, hydration, exercise, alcohol, medicines, and acute illness may alter results. It cannot diagnose testosterone deficiency, sexual dysfunction, or a specific liver or kidney disorder alone. |
| Lipid Panel Test lipid profile, cholesterol panel, total cholesterol, LDL-C, HDL-C, triglycerides Use status: First-line | Measures major circulating lipids to support cardiovascular-risk assessment in men with erectile dysfunction, obesity, diabetes risk, or treatment considerations. Higher atherogenic cholesterol or triglycerides, or lower HDL cholesterol, may add risk context; interpretation depends on the full cardiovascular profile.7 | Serum; the linked product requires at least a 9-hour fast with water only. Meals, alcohol, acute illness, medicines, and recent weight change may alter results. It cannot establish the cause of erectile dysfunction or determine overall cardiovascular risk by itself. |
| A1c Test A1C, HbA1c, hemoglobin A1c, glycated hemoglobin Use status: First-line | Estimates average glucose exposure over the preceding two to three months. It may identify abnormal glucose regulation that contributes to vascular or nerve-related sexual-health risk and can support diabetes or prediabetes evaluation and monitoring. Higher values require interpretation with the clinical context.8 | Whole blood; fasting is not required. Anemia, hemoglobin variants, kidney disease, recent blood loss or transfusion, and altered red-cell turnover may distort results. It cannot identify the mechanism of erectile dysfunction or detect every glucose disorder in isolation. |
| Insulin Test fasting insulin, serum insulin Use status: Targeted | Measures circulating insulin at the time of collection for selected evaluation of insulin production or insulin resistance within a broader metabolic assessment. High or low results are context-dependent and must be read with glucose, meal timing, medicines, and physiology.9 | Serum; the linked product requires at least an 8-hour fast with water only. Food intake, collection timing, blood glucose, diabetes medicines, and acute stress may affect results. It cannot diagnose insulin resistance from one universal cutoff or explain testosterone-related symptoms by itself. |
| Ferritin, Iron and Total Iron Binding Capacity Panel iron studies, ferritin, serum iron, TIBC, transferrin saturation Use status: Targeted | Measures stored iron and circulating iron-binding measures to evaluate iron deficiency, anemia, or iron overload as alternative contributors to fatigue or selected pituitary or testicular patterns. Low ferritin commonly supports iron depletion; high ferritin may reflect iron loading, inflammation, liver disease, or other causes.10 | Serum; the linked product calls for morning collection after at least an 8-hour fast with water only. Inflammation, liver disease, supplements, recent illness, timing, and fasting status may alter results. It cannot diagnose a specific iron disorder or explain sexual symptoms by itself. |
Educational framework—not a diagnostic or treatment algorithm. This pathway shows how clinicians commonly organize the laboratory question. It does not diagnose testosterone deficiency and does not recommend testosterone therapy.
The Endocrine Society emphasizes symptoms plus consistently low, accurately measured testosterone and repeat morning testing; it also recommends against general-population screening. [1] [2]
Educational framework—not a diagnostic or treatment algorithm. A clinician may modify every step based on symptoms, examination, family history, previous results, medications, fertility goals, and the consequences of a false-positive or false-negative result.
| Patient question | History and context to review | Focused laboratory starting point | Possible next step if results or context warrant | Consequence of indiscriminate testing |
|---|---|---|---|---|
| “Could my symptoms reflect low testosterone?” | Specific symptoms, duration, morning erections/libido, illness, sleep, body-weight change, medications, opioid or corticosteroid exposure, prior hormone/anabolic use, fertility plans | Early-morning total testosterone when symptoms/signs support testing | Repeat a separate morning value; then selected SHBG, reliable free testosterone, LH/FSH, prolactin, thyroid, CBC, or metabolic tests | A single mistimed or illness-affected value may be mislabeled as disease |
| “Why are total testosterone and symptoms discordant?” | Age, obesity, diabetes, liver or thyroid disease, medications, assay method, timing | SHBG plus albumin and a reliable free-testosterone approach | Review assay method and repeat under standardized conditions | Unreliable direct free-testosterone methods or unvalidated calculations may add confusion |
| “Could the problem be pituitary or testicular signaling?” | Confirmed low-testosterone pattern, fertility, testicular history, headaches/visual symptoms, medication exposure | LH and FSH; selected prolactin | Clinician-directed pituitary, genetic, imaging, semen, or testicular evaluation | Ordering pituitary hormones without a supported clinical question may reveal minor variations that do not explain symptoms |
| “What should be monitored during prescribed testosterone therapy?” | Original diagnosis, formulation and dose timing, symptoms, adverse effects, fertility, prostate risk, sleep apnea, cardiovascular history | Testosterone timed to formulation, CBC/hematocrit, and risk/age-appropriate PSA discussion; targeted CMP, lipids, A1C, estradiol | Prescribing clinician interprets trends and decides whether examination or urologic review is needed | Self-directed testing cannot safely replace treatment supervision or dose decisions |
| “Should I have a PSA test?” | Age, ancestry/race, family history, previous PSA, life expectancy, urinary symptoms, prior prostate procedures, medications, personal preferences | Total PSA only after a screening or diagnostic-use discussion appropriate to the situation | Repeat after transient influences resolve; selected free and total PSA, risk calculator, MRI, urology evaluation, or biopsy | Screening can produce false positives, overdiagnosis, anxiety, biopsy complications, and treatment harms |
| “Could erectile dysfunction signal another health problem?” | Onset, severity, morning/nocturnal erections, exertional symptoms, medications, smoking, vascular risk, sleep, mental health, relationship context | A1C, glucose, lipid panel, and morning total testosterone when indicated | Blood pressure, cardiovascular risk assessment, genital/neurologic examination, sleep or mental-health evaluation | A large hormone panel may miss the vascular, medication-related, neurologic, or psychological cause |
| “Could hormones explain infertility?” | Duration, semen history, prior testosterone/anabolic use, surgeries, testicular injury, medications, partner evaluation | Morning total testosterone plus LH/FSH in selected cases | Semen analysis and reproductive-urology evaluation are central; additional testing is clinician-directed | Hormone blood tests alone cannot evaluate sperm count, motility, morphology, anatomy, or both partners’ factors |
This section explains monitoring literacy for people already working with a prescribing clinician. It does not recommend starting testosterone, select a product, set a dose, define a personal target, or advise changing treatment.
| Monitoring domain | Before clinician-managed therapy | Early follow-up | Ongoing review | Why it matters | Safety boundary |
|---|---|---|---|---|---|
| Indication and baseline diagnosis | Compatible symptoms/signs plus at least two appropriately timed low testosterone measurements; clarify cause | Reassess symptoms, adverse effects, adherence, and whether the original indication remains valid | Periodic clinician review | Prevents treatment of a transient or misclassified result | This page does not recommend TRT or identify who should receive it |
| Total testosterone | Document pretreatment value using an accurate assay | Collect at a formulation-appropriate time chosen by the prescriber | Periodic measurement under comparable timing; AUA suggests every 6–12 months once stable | Assesses exposure and trend | Do not compare values drawn at different points in a dosing cycle as if they were equivalent; do not self-adjust |
| Free testosterone, SHBG, albumin | Use when indicated by borderline total testosterone or altered SHBG | Repeat only when it addresses an interpretation question | As clinically needed | Helps interpret discordant total testosterone | Not automatically required at every monitoring visit |
| CBC, hemoglobin and hematocrit | Baseline blood count and identification of preexisting elevation or anemia | Early follow-up according to the prescriber’s monitoring plan | Periodic monitoring | Detects erythrocytosis or other blood-count changes | Dehydration, altitude, smoking, lung disease, and sleep apnea can also raise hematocrit; an abnormality requires prescriber review, not self-directed dosing |
| PSA and prostate-risk discussion | Age-, risk-, symptom-, and preference-appropriate prostate assessment before treatment when relevant | Endocrine Society guidance calls for prostate-risk reassessment 3–12 months after starting in men who choose monitoring | Thereafter, follow age- and risk-appropriate prostate guidance | Tracks prostate-related risk context and changes from baseline | PSA is not a cancer diagnosis; screening guidance differs by organization and requires shared decision-making |
| Estradiol | Not universal; obtain when symptoms or the clinician’s plan provide a reason | Repeat for persistent breast symptoms, unexpected results, or selected monitoring | As clinically indicated | May clarify estrogen-related symptoms or treatment effects | Do not use one estradiol value as an automatic instruction to add or change medication |
| CMP and liver/kidney context | Selected baseline based on overall health, medicines, and formulation | Repeat when clinically indicated | Periodic only when the treatment or comorbidities warrant it | Identifies broader safety and alternative-cause issues | Routine frequency is not identical for every formulation or patient |
| Lipid panel, A1C/glucose, blood pressure, weight, sleep | Establish cardiovascular and metabolic context | Reassess if risk factors, symptoms, or treatment-related changes emerge | Follow standard preventive and disease-monitoring guidance | ED and metabolic disease can coexist; cardiometabolic health matters independently of testosterone | TRT is not a glucose-control or cardiovascular-risk treatment |
| Fertility and testicular function | Document current and future fertility goals before treatment | Revisit if reproductive plans change | As needed | Exogenous testosterone can suppress gonadotropins and sperm production | Hormone blood tests do not replace semen analysis or reproductive-urology evaluation |
| Clinical response and safety | Document baseline symptoms, examination findings, blood pressure, sleep-apnea risk, urinary symptoms, and comorbidities | Assess response, side effects, adherence, and new contraindications | Periodic clinician review | Treatment monitoring is more than a lab checklist | Laboratory values should never be the sole basis for starting, stopping, or changing a prescription |
The FDA requested testosterone-label updates in June 2026 after reviewing newer evidence. The changes included removing a prior age-related limitation-of-use statement and revising safety information related to prostate cancer and benign prostatic hyperplasia. That regulatory change does not replace an accurate diagnosis, shared decision-making, fertility counseling, or ongoing safety monitoring. [10]
| Measure | What it measures | When it may be useful | Potential advantage | Major limitation | Safe interpretation |
|---|---|---|---|---|---|
| Total PSA | All measured PSA in circulation | Shared-decision screening, evaluation of prostate symptoms, or monitoring | Most established blood marker for prostate risk assessment and follow-up | Can be elevated by benign enlargement, inflammation, infection, ejaculation, cycling, and procedures; may be low despite cancer | No single result diagnoses or excludes cancer |
| Free PSA | PSA circulating unbound to proteins | Selected follow-up when a total PSA is in an indeterminate range and additional risk context may change next steps | Can refine risk discussions without immediately moving to an invasive procedure | Results overlap between benign and malignant conditions; utility depends on the total-PSA range and population | Interpret only with total PSA, age, risk, symptoms, examination, and trend |
| Percent free PSA | Free PSA divided by total PSA × 100 | Risk stratification in selected men | Expresses the relationship between the two measurements | There is no universal percentage that proves or rules out cancer; thresholds and decisions vary | Do not use a single online cutoff as a biopsy decision |
| PSA trend | Change in total PSA over time | Follow-up of screening, symptoms, or a known prostate condition | May distinguish a transient result from a persistent pattern | Changes in assay, infection, procedures, medicines, and testing conditions can mimic a trend | Confirm unexpected elevations and use clinician-directed follow-up |
Percent free PSA is calculated from free PSA divided by total PSA and expressed as a percentage. It may provide additional risk context in selected men with a total PSA result that prompts further evaluation. It is not a stand-alone cancer test, and no single percentage should be presented as a universal biopsy rule. Age, prostate size, trend, infection or inflammation, medications, family history, examination, risk calculators, MRI, and patient preferences may influence the next step.
Erectile dysfunction is a symptom, not a single laboratory diagnosis. It may involve more than one contributor, and a normal testosterone result does not end the evaluation.
| Contributor domain | Clues that may raise the question | Laboratory tests that may add information | Other evaluation | Key caution |
|---|---|---|---|---|
| Vascular and cardiometabolic | Gradual ED, reduced exercise tolerance, hypertension, diabetes risk, obesity, smoking history | A1C, fasting glucose/CMP, lipid panel; selected kidney or inflammatory testing based on risk | Blood pressure, cardiovascular risk calculation, pulses/vascular examination, medication review; urgent evaluation for cardiac symptoms | ED can be a risk marker for underlying cardiovascular disease; a hormone-only workup is incomplete |
| Hormonal and endocrine | Low libido, fewer spontaneous erections, infertility, breast symptoms, testicular changes, pituitary clues | Morning total testosterone; repeat if low; free testosterone/SHBG, LH/FSH, prolactin, estradiol, or thyroid testing only as indicated | Genital examination, medication review, pituitary or fertility evaluation when appropriate | Most ED is not diagnosed by a testosterone result alone |
| Medication and substance related | Symptoms begin after a medication change; opioid, glucocorticoid, antidepressant, antihypertensive, alcohol, or anabolic-agent exposure | Tests selected from the suspected effect; broad panels are rarely the first step | Prescriber and substance-use review | Never stop a prescription abruptly based on an article or lab result |
| Neurologic, structural, pelvic, or prostate related | Numbness, weakness, pelvic surgery/radiation, penile curvature, pelvic pain, urinary symptoms | Urinalysis or PSA in selected contexts; hormone tests only if other clues exist | Neurologic/genital examination, imaging, urology evaluation | Sudden neurologic deficits, acute urinary retention, or severe testicular pain require prompt care |
| Sleep, mood, stress, and relationship | Variable erections, situational pattern, depression/anxiety, major stress, poor sleep, suspected sleep apnea | CBC, TSH/free T4, A1C, or testosterone only when the history supports them | Sleep evaluation, mental-health and relationship assessment | Psychological and physical contributors can coexist; neither should be dismissed |
| Mixed or unclear | More than one risk factor or discordant symptoms and results | Focused testing guided by the highest-impact questions rather than an indiscriminate panel | Primary care, urology, endocrinology, or cardiology evaluation as appropriate | A staged evaluation reduces incidental findings and missed nonlaboratory causes |
Chest pressure, shortness of breath, fainting, new neurologic deficits, or other acute symptoms should not be evaluated through routine ED laboratory testing. Seek prompt medical or emergency assessment.
| Testing option | Typical contents or focus | When it may be useful | Advantages | Limitations | Risk of incidental findings | Questions to ask before ordering |
|---|---|---|---|---|---|---|
| Single biomarker | One defined analyte such as total testosterone, SHBG, prolactin, or PSA | A focused question, repeat confirmation, or trend using the same method | Lower chance of unrelated findings; easier interpretation | May miss context needed for a borderline or discordant result | Low | Will this result answer my specific question? Does it need a paired test or repeat? |
| Focused hormone combination | Examples include total plus free testosterone, or testosterone with SHBG and albumin | When binding proteins or borderline total testosterone affect interpretation | Keeps testing tied to the endocrine question | Exact calculation method and component list must be verified | Low to moderate | Is free testosterone measured or calculated? Which method and reference interval are used? |
| Pituitary–testicular combination | Testosterone with LH and FSH; prolactin only when the history or pattern supports it | After low testosterone is confirmed or infertility is being evaluated | Can help localize the signaling pattern | Does not replace semen analysis, examination, or pituitary evaluation | Moderate | Am I confirming a persistent result, or ordering a broad panel before the basic question is established? |
| TRT monitoring panel | May combine testosterone, CBC/hematocrit, PSA, estradiol, or metabolic measures depending on the named panel | Only within a clinician-directed monitoring plan | Convenient grouping of commonly reviewed safety and response measures | Panel contents may not match the prescriber’s formulation-specific timing or monitoring plan | Moderate | Does my prescriber want every component, at this time, with this formulation? |
| Broad men’s hormone panel | Multiple androgen, pituitary, thyroid, adrenal, or metabolic tests | Selected complex evaluations when each component has a defined purpose | Can reduce repeat blood draws when thoughtfully selected | Higher chance of incidental, borderline, or uninterpretable findings; more expensive is not automatically more useful | Moderate to high | What decision will each result change? Who will interpret discordant values? |
| Prostate-focused option | Total PSA alone or total plus free PSA; specialist panels may include other markers | Shared-decision screening, a selected elevated result, symptoms, or monitoring | Can match the specific prostate question | No blood panel diagnoses cancer; specialist tests may not be appropriate for broad screening | Moderate | Is this screening, symptom evaluation, or follow-up? Are transient PSA influences controlled? |
Before selecting a panel, identify the decision each component could change. A test that cannot alter the next step may add cost and incidental findings without adding useful information. Verify every panel’s current component list on the live Ulta Lab Tests page immediately before ordering or publication.
| Preferred name | Common aliases or abbreviations | Practical note |
|---|---|---|
| Total testosterone | TT, total T, serum testosterone | Includes protein-bound and free fractions |
| Free testosterone | FT, free T, calculated free testosterone, equilibrium-dialysis free testosterone | Confirm method; results from different methods are not interchangeable |
| Bioavailable testosterone | BAT, non-SHBG-bound testosterone | Usually free plus albumin-bound testosterone |
| Sex hormone–binding globulin | SHBG | Binding protein used to interpret total versus free testosterone |
| Luteinizing hormone | LH, interstitial cell–stimulating hormone in older terminology | Pituitary signal to testicular Leydig cells |
| Follicle-stimulating hormone | FSH | Pituitary signal involved in spermatogenesis |
| Prolactin | PRL | Pituitary hormone; targeted rather than universal testing |
| Estradiol | E2, sensitive estradiol, ultrasensitive estradiol | Method matters at the lower concentrations often present in men |
| Dehydroepiandrosterone sulfate | DHEA-S | Adrenal androgen; not a routine low-testosterone screen |
| Prostate-specific antigen | PSA, total PSA | Prostate marker used for risk assessment, symptom evaluation, and monitoring |
| Free PSA | fPSA | Unbound PSA fraction |
| Percent free PSA | % free PSA, free-to-total PSA ratio | Calculated from free PSA divided by total PSA times 100 |
| Complete blood count | CBC, Hgb, Hct | Hematocrit is the red-cell volume percentage reported within the CBC |
| Hemoglobin A1C | A1C, HbA1c | Longer-term glucose-exposure marker; no fasting required |
This crosswalk does not include laboratory order numbers. Similar names can refer to different methods or calculated values, so the exact test description remains important.
| Factor | Tests commonly affected | How the factor may alter results | General preparation guidance | Important caution |
|---|---|---|---|---|
| Time of day | Total and free testosterone | Testosterone usually has diurnal variation and may be lower later in the day | For initial evaluation and confirmation, use an early-morning collection after usual sleep unless a clinician gives different instructions | Shift workers and men with irregular sleep should discuss timing relative to their sleep cycle |
| Fasting and recent food intake | Testosterone confirmation, glucose, insulin, triglycerides, some panels | Food intake can alter glucose, insulin, triglycerides, and may affect testosterone interpretation | Follow the exact order’s fasting instructions; water is generally permitted unless stated otherwise | Do not fast longer than instructed, especially with diabetes or medical conditions |
| Acute illness or recovery | Testosterone, prolactin, CBC, CMP, lipids, PSA | Illness, inflammation, hospitalization, or major physiologic stress can temporarily alter results | When testing is elective, consider confirming after recovery in coordination with a clinician | Urgent symptoms should be evaluated immediately rather than delayed for “cleaner” testing |
| Sleep loss, obstructive sleep apnea, or shift work | Testosterone, hematocrit, glucose-related tests | Disrupted sleep can affect hormone patterns; sleep apnea may contribute to elevated hematocrit and sexual symptoms | Document recent sleep and use consistent collection timing | A blood test does not diagnose sleep apnea |
| Recent strenuous exercise | Testosterone, prolactin, liver-associated enzymes, creatinine, PSA after cycling | Exercise can temporarily shift several biomarkers; cycling may raise PSA in some men | Avoid unusually strenuous activity before testing when the laboratory or clinician advises; use similar routines for trends | Do not delay emergency evaluation after exercise-related chest pain or severe symptoms |
| Ejaculation and prostate stimulation | PSA | Ejaculation and some prostate-related activities/procedures can transiently raise PSA | Follow the product and clinician instructions; NCI notes avoiding activities that may raise PSA for two days before testing | Disclose recent urinary procedures, biopsy, infection, or inflammation |
| Hydration | CBC/hematocrit, CMP, kidney markers | Dehydration can concentrate blood components and affect several results | Maintain usual hydration unless medically restricted | Do not overhydrate to manipulate a result |
| Alcohol | Estradiol, liver tests, triglycerides, glucose | Recent or heavy alcohol use may alter metabolic and liver-related measures | Follow laboratory instructions and report relevant use honestly | Testing cannot determine a safe alcohol amount for an individual |
| Biotin and supplements | Selected hormone, thyroid, and immunoassay-based tests | High-dose biotin and other supplements can interfere with some assay systems | List all vitamins, supplements, and doses; follow the laboratory or clinician’s instructions | Never stop a medically necessary product without professional guidance |
| Prescription and nonprescription medicines | Testosterone, SHBG, prolactin, PSA, thyroid, metabolic tests | Opioids, glucocorticoids, antipsychotics, finasteride/dutasteride, hormones, and many other drugs can alter results | Provide a complete medication list and timing | Do not stop or change a medicine to “normalize” a result without the prescriber |
| Hormone therapy or anabolic agents | Testosterone, LH, FSH, estradiol, SHBG, CBC, PSA, fertility measures | Exogenous hormones can change endocrine feedback, blood counts, prostate markers, and sperm production | Record product, dose, route, schedule, and time since the last dose for the interpreting clinician | The article does not provide dose or cycling advice |
| Laboratory method and specimen handling | Testosterone, free testosterone, estradiol, PSA | Different assay methods, equations, reference intervals, and preanalytical handling can create apparent changes | For trends, use the same laboratory and method when practical; compare units carefully | A change after switching laboratories may be analytical rather than biological |
Never stop a prescription medication, prescribed hormone, or nonprescription product solely to prepare for a test unless the prescribing or supervising professional instructs you to do so. Report relevant medicines, supplements, recent procedures, illness, exercise, and collection timing so the result can be interpreted safely.
A laboratory reference interval describes values observed in a defined comparison population using a particular method. It is not automatically a diagnostic threshold, screening cutoff, or treatment target. A value can be inside a reference interval yet still require attention because of symptoms or trend; a value outside the interval may be temporary, expected in context, or unrelated to the patient’s main question.
Biological variation includes normal day-to-day and time-of-day change. Analytical variation comes from the measurement method. Preanalytical variation includes collection time, fasting status, recent illness, exercise, specimen handling, and medications. Units and methods must match before comparing results. Testosterone values from different assays and PSA values from different laboratories may not be directly comparable.
Trends can add context, but trend interpretation also requires consistent timing and methods. A repeat test may confirm whether an unexpected value persists. A confirmatory test may use a different method or answer a narrower question. Discordant results—such as symptoms with a non-low total testosterone or a low total testosterone with a non-low reliable free testosterone—should prompt a review of SHBG, timing, assay method, illness, medicines, and alternative causes rather than an automatic conclusion.
For a fuller explanation of reference intervals, units, flags, biological variation, and trends, see How to Read and Understand Your Lab Results.
| Term | What it means | How it is established | How it is used | Why it may differ from another laboratory or guideline | Patient caution |
|---|---|---|---|---|---|
| Laboratory reference interval | The range that contains results from a defined reference population using a specific method | Established by the laboratory or adopted from a validated source | Flags results for attention | Populations, methods, units, and statistical approaches differ | A flag is not a diagnosis, and an unflagged result does not guarantee health |
| Diagnostic criterion | A rule used with symptoms, signs, repeat testing, and other evidence to define a condition | Established by clinical guidelines and evidence | Supports a clinician’s diagnosis | May use more than one test, repeated values, or context not shown on a lab report | Do not substitute a reference-range flag for a diagnosis |
| Screening cutoff | A value used to identify who may benefit from further assessment | Chosen to balance missed cases and false positives in a population | Triggers discussion or additional testing | Cutoffs vary with population, age, risk, and guideline | Crossing a cutoff does not prove disease |
| Treatment target | A clinician-selected range or goal during therapy | Based on evidence, formulation, symptoms, safety, and individual circumstances | Guides follow-up within a treatment plan | May not equal the laboratory reference interval | Do not self-adjust a prescription from a target or one result |
| Monitoring threshold | A change or level that prompts reassessment for safety or effectiveness | Defined by guidelines, drug labeling, or specialist protocols | Signals need for clinical review | Timing, baseline, method, and confirmation matter | A threshold is a prompt for review, not an automatic treatment instruction |
| Trend | The direction and magnitude of repeated results over time | Created from serial measurements | May clarify persistence or change | Meaningful comparison requires similar timing, preparation, units, and methods | A trend does not override symptoms, examination, or urgent findings |
Educational examples only. The values and intervals below are fictional. They do not establish universal reference ranges, diagnostic thresholds, or treatment targets.
| Test | Fictional value | Fictional sample-laboratory interval | Flag | Collection context | How to reason about it |
|---|---|---|---|---|---|
| Initial total testosterone | 265 ng/dL | Sample laboratory interval: 300–1,000 ng/dL | Low | Drawn at 4:20 p.m. during a febrile respiratory illness after poor sleep | The value is below this fictional laboratory’s interval, but timing and illness make it unsuitable as a stand-alone diagnosis |
| Repeat total testosterone | 342 ng/dL | Same sample laboratory interval: 300–1,000 ng/dL | Not flagged | Drawn at 8:05 a.m. after recovery, fasting, at the same laboratory | The repeat is different from the first result; symptoms and binding-protein context still matter |
| SHBG | 13 nmol/L | Sample laboratory interval: 10–50 nmol/L | Low-normal | Same morning sample | A lower SHBG may make total testosterone look lower relative to the free fraction |
| Calculated free testosterone | Within the sample laboratory’s stated interval | Method-specific interval | Not flagged | Calculated from same-day total testosterone, SHBG, and albumin | This pattern would prompt review of symptoms, obesity/insulin resistance, sleep, medicines, and assay method—not an automatic diagnosis or treatment decision |
Questions for professional follow-up: Were both samples measured with the same accurate method? Were symptoms compatible and persistent? Was SHBG altered? Does the LH/FSH pattern support a testicular or pituitary/hypothalamic direction? Could sleep, obesity, illness, medication exposure, or another condition explain the result? Are fertility plans relevant?
What this example does not show: It does not diagnose testosterone deficiency and does not support a treatment decision. It demonstrates why timing, recovery from illness, repeat testing, and binding-protein context matter.
| Test | Fictional value | Fictional sample-laboratory interval or rule | Flag | Collection and trend context | How to reason about it |
|---|---|---|---|---|---|
| Total PSA | 4.4 ng/mL | Sample laboratory flag: above 4.0 ng/mL | High | Previous result 3.0 ng/mL one year earlier; vigorous cycling two days before collection; new urinary burning | An increase deserves follow-up, but transient influences and infection/inflammation must be considered; the result is not a cancer diagnosis |
| Free PSA | 0.70 ng/mL | No universal stand-alone reference interval | Not independently flagged | Collected with total PSA | Free PSA is used with total PSA, not interpreted alone |
| Percent free PSA | 16% | No universal diagnostic cutoff | Risk-context result | Calculated from the paired results | This percentage may add risk context, but it cannot determine whether cancer is present |
Questions for professional follow-up: Are urinary symptoms consistent with infection or inflammation? Should the PSA be repeated after transient influences resolve? Is free PSA or another risk tool useful? What were prior values and laboratory methods? Does risk history justify urology review, MRI, or biopsy discussion?
What this example does not show: It does not diagnose prostate cancer or benign disease. It demonstrates why a result, trend, collection context, symptoms, and follow-up pathway must be considered together.
Broad hormone screening is unlikely to help when there are no relevant symptoms, signs, treatment-monitoring needs, reproductive questions, previous abnormalities, or risk factors. The Endocrine Society recommends against routine general-population screening for hypogonadism. [1]
Repeat testing is not automatic. It should be timed to answer a question, allow a temporary influence to resolve when appropriate, and avoid delaying care when a result or symptom requires prompt evaluation.
Routine direct-access testing is not a substitute for emergency or time-sensitive assessment. Seek prompt professional care for:
This pillar owns the broad “men’s health blood tests” topic. The following articles should answer narrower questions and link back to this page as their primary parent.
These links are organized by clinical purpose rather than panel size. Each individually orderable Ulta Lab Tests product discussed in this guide is linked to its current product page. Select a test only when it addresses a defined question, and review the live page for the current specimen, preparation, methodology, availability, components, and price before ordering.
Semen analysis, physical examination, imaging, prostate biopsy, electrocardiography, sleep studies, and other specialist-directed evaluations are discussed where clinically relevant, but they are not presented as Ulta individual-test product links in this article.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Men's Hormone Panel Use status: Targeted panel | General male-hormone option that may group related tests when its current live components match a defined baseline or monitoring question. | Verify the current component list, specimen, preparation, methodology, availability, and clinical fit. A larger panel is not automatically better and can increase incidental findings. |
| Hormone Testing for Men: 10 Common Lab Tests Use status: Targeted panel | Broader male-hormone testing option for a defined question when each current component is justified. | Confirm all live components and methods before ordering. Broad testing can produce borderline or unrelated findings that require follow-up. |
| HH-1. Hormone Health - Men Use status: Targeted panel | Hormone-health panel that may be useful when the live component set matches a focused evaluation or monitoring plan. | Verify current contents, timing, and intended use. The panel name alone does not establish appropriateness or diagnostic meaning. |
| Hormone Health, Men - Advanced Use status: Specialist-directed or targeted panel | Broader hormone-health option for selected questions when each live component has a defined purpose. | Confirm current contents and methods. More analytes increase the chance of incidental, borderline, or discordant results. |
| Testosterone Replacement Package I (Estradiol, Ultrasensitive) Use status: Clinician-directed monitoring | May group selected testosterone-therapy monitoring measures when its live components match the prescriber’s plan. | Verify exact components, collection timing relative to treatment, preparation, and current product status. Do not change therapy from a panel result alone. |
| Testosterone Replacement Package II (Estradiol, Ultrasensitive) Use status: Clinician-directed monitoring | May group selected testosterone-therapy monitoring measures when the current panel matches the clinician’s baseline or follow-up question. | Verify components, methods, preparation, and formulation-specific timing. The package name does not replace a prescriber’s monitoring plan. |
| Testosterone Replacement Package Plus Use status: Clinician-directed monitoring | Broader clinician-managed testosterone-therapy monitoring option when every current component is relevant. | Confirm the live component list, timing, and need for each measure. Broader monitoring can increase incidental findings and cost. |
| Testosterone Replacement Therapy (TRT) with Estradiol, Ultrasensitive Use status: Clinician-directed monitoring | May support a defined clinician-managed TRT monitoring question that includes an ultrasensitive estradiol measurement. | Verify live components and timing. Estradiol is not automatically indicated for every person receiving testosterone therapy. |
| Sex & Energy Lab Panel (Male) Use status: Targeted panel | Sexual-health and energy-focused option when its current tests match a defined clinical question. | Symptoms are nonspecific. Verify components and avoid interpreting the panel as proof of a hormonal cause. |
| Hormone Panel (Male) Assessment, Comprehensive Use status: Specialist-directed or targeted panel | Broad male-hormone assessment option for selected complex questions when every live component is justified. | Verify current components, methods, timing, and clinical fit. Broad panels raise incidental-finding and interpretation risk. |
| Testosterone Replacement Therapy (TRT) Panel Use status: Clinician-directed monitoring | May group commonly reviewed baseline or monitoring tests within a clinician-directed testosterone-therapy plan. | Confirm the live component list, preparation, methods, collection timing, and whether every included test is needed. |
| Testosterone Treatment Evaluation Use status: Clinician-directed monitoring | Treatment-monitoring option when the live components and timing match the prescriber’s question. | Verify current contents, preparation, methods, and treatment-specific timing. Results do not provide stand-alone dose instructions. |
Where direct-access testing is available and appropriate, eligible patients may review available laboratory tests online, view the displayed price before completing an order, obtain the required order or requisition through the service’s current process, use a participating collection location, and access completed results through their account. Results can support a more informed conversation with a qualified healthcare professional.
Availability, preparation, collection requirements, and ordering rules can vary by test and location. Confirm the live product page and current policies before ordering. Direct-access testing does not replace emergency care, a physical examination, imaging, semen analysis, biopsy, or clinician-directed treatment monitoring.
See Direct-Access Lab Testing: How It Works and What to Expect for the ordering, preparation, collection, result-delivery, and follow-up process, and use the participating patient service-center locator to review current collection options.
No. Current guidance emphasizes compatible symptoms or signs plus consistently low, accurately measured testosterone. A low result is generally confirmed with a separate early-morning measurement, and timing, illness, sleep, food intake, medications, assay method, and SHBG context may matter.
For evaluation of possible deficiency, early-morning collection after usual sleep is preferred because testosterone is generally highest then. Shift workers or people with unusual sleep schedules need individualized timing. Follow the specific test’s fasting and preparation instructions.
The Endocrine Society’s diagnostic pathway calls for repeat morning fasting total testosterone. Food intake can affect results in some circumstances. Follow the laboratory’s instructions and keep repeat collections as comparable as possible.
Total testosterone includes protein-bound and unbound hormone. Free testosterone is the small unbound fraction. Free testosterone may add context when total testosterone is borderline, symptoms and total testosterone disagree, or SHBG is likely to be abnormal.
SHBG binds testosterone strongly. Low or high SHBG can make total testosterone appear lower or higher relative to the biologically available fractions. SHBG is interpreted with total testosterone, albumin, symptoms, health conditions, medications, and assay method.
After a low-testosterone pattern is supported, LH and FSH may help distinguish a primarily testicular pattern from a pituitary or hypothalamic signaling pattern. They do not identify the exact cause without additional clinical evaluation.
No. These are targeted tests. Prolactin may be useful with selected central, medication, sexual, headache, visual, or breast symptoms. Estradiol may help with breast symptoms or selected monitoring. DHEA-S is mainly for defined adrenal-androgen questions.
They can influence testosterone concentrations and symptoms. Obesity often lowers SHBG and may lower total testosterone; acute illness, sleep disruption, calorie restriction, and some medications can also alter results. Interpretation should account for the collection context.
Yes. ED can be associated with vascular disease and cardiometabolic risk, especially when it develops gradually. Evaluation may include blood pressure, diabetes and lipid assessment, medication review, and cardiovascular risk review—not testosterone alone.
The plan may include testosterone timed to the formulation, CBC/hematocrit, and risk-appropriate PSA discussion or testing, with selected metabolic, liver, or estradiol measurements. The prescribing clinician determines the schedule and interprets changes.
No. PSA may rise with cancer, benign prostate enlargement, inflammation, infection, urinary retention, recent procedures, and other influences. A persistent or concerning result may lead to repeat testing, risk assessment, imaging, urology evaluation, or biopsy.
Percent free PSA is free PSA divided by total PSA, expressed as a percentage. It may add risk context in selected situations, but no single percentage diagnoses cancer or serves as a universal biopsy rule.
No single approach fits every man. Recommendations emphasize informed or shared decision-making based on age, risk factors, health, prior results, life expectancy, and preferences. As of August 7, 2026, the USPSTF page stated that this topic was being updated; its current final recommendation remained an individual screening decision for ages 55–69 and no routine screening at age 70 or older. Recheck current guidance when making a screening decision.
Hormone tests can provide selected information, but they cannot measure sperm count, movement, shape, semen volume, reproductive anatomy, or all partner-related factors. Semen analysis and reproductive evaluation are often central.
Do not start, stop, increase, decrease, or change prescribed testosterone based only on a self-interpreted result. Collection timing, formulation, symptoms, hematocrit, PSA context, adverse effects, and other findings need review by the prescribing clinician.
Men’s health blood tests can help evaluate testosterone status, binding-protein effects, pituitary-to-testis signaling, selected contributors to sexual symptoms, prostate-related risk, treatment safety, and cardiometabolic health. The most responsible approach begins with a defined question, uses properly timed and accurately measured tests, repeats or confirms results when appropriate, and avoids broad panels that are unlikely to change the next step.
A single testosterone result does not diagnose testosterone deficiency. PSA is not a cancer diagnosis. Normal results do not guarantee health, and abnormal results do not automatically establish disease. Symptoms, examination findings, assay methods, timing, medications, illness, sleep, body composition, previous values, family history, and patient preferences all affect interpretation.
Use the guide to reading and understanding lab results for help with ranges, flags, units, and trends; review how direct-access lab testing works before ordering; and explore the focused testosterone, TRT-monitoring, erectile-dysfunction, PSA, and prostate subpillars above. Select testing carefully and bring unexpected or clinically important results to a qualified healthcare professional.
The numbered source markers in the three detailed test inventories point to the claim-matched source groups below. Every source was rechecked on August 7, 2026; revalidate update dates and guidance before publication.
Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.
These tests address cardiometabolic and organ-function context relevant to erectile dysfunction, obesity, insulin resistance, cardiovascular risk, and treatment monitoring.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
